Investigational Drug Information for VERU-111
✉ Email this page to a colleague
What is the drug development status for VERU-111?
VERU-111 is an investigational drug.
There have been 6 clinical trials for VERU-111.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 24th 2021.
The most common disease conditions in clinical trials are Severe Acute Respiratory Syndrome, Breast Neoplasms, and Coronavirus Infections. The leading clinical trial sponsors are Veru Inc. and [disabled in preview].
There are eight US patents protecting this investigational drug and one hundred international patents.
Summary for VERU-111
| US Patents | 8 |
| International Patents | 100 |
| US Patent Applications | 30 |
| WIPO Patent Applications | 12 |
| Japanese Patent Applications | 5 |
| Clinical Trial Progress | Phase 2 (2021-06-24) |
| Vendors | 29 |
Recent Clinical Trials for VERU-111
| Title | Sponsor | Phase |
|---|---|---|
| P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC . | Veru Inc. | Phase 2 |
| Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer | Veru Inc. | Phase 2 |
| Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent | Veru Inc. | Phase 3 |
Clinical Trial Summary for VERU-111
Top disease conditions for VERU-111
Top clinical trial sponsors for VERU-111
US Patents for VERU-111
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| VERU-111 | ⤷ Sign Up | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (Knoxville, TN) | ⤷ Sign Up |
| VERU-111 | ⤷ Sign Up | Compounds for treatment of cancer | GTX, INC. (Memphis, TN) UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (Noxville, TN) | ⤷ Sign Up |
| VERU-111 | ⤷ Sign Up | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (Knoxville, TN) | ⤷ Sign Up |
| VERU-111 | ⤷ Sign Up | Compounds for treatment of cancer | GTX, Inc. (Memphis, TN) University of Tennessee Research Foundation (Knoxville, TN) | ⤷ Sign Up |
| VERU-111 | ⤷ Sign Up | Compounds for treatment of cancer | GTx, Inc. (Memphis, TN) University of Tennessee Research Foundation (Knoxville, TN) | ⤷ Sign Up |
| VERU-111 | ⤷ Sign Up | Compounds for treatment of cancer | GTX, INC. (Memphis, TN) UNIVERSITY OF TENNESSEE (Knoxville, TN) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for VERU-111
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| VERU-111 | Australia | AU2014225761 | 2033-03-05 | ⤷ Sign Up |
| VERU-111 | Australia | AU2018226470 | 2033-03-05 | ⤷ Sign Up |
| VERU-111 | Canada | CA2904338 | 2033-03-05 | ⤷ Sign Up |
| VERU-111 | China | CN105163584 | 2033-03-05 | ⤷ Sign Up |
| VERU-111 | China | CN109568312 | 2033-03-05 | ⤷ Sign Up |
| VERU-111 | European Patent Office | EP2964028 | 2033-03-05 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
